Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Heart Matters

Acoramidis reduces all-cause mortality in ATTR-CM

Daniel Judge at AHA
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    AHA 2024 - Daniel Judge discusses the findings from the ATTRibute-CM-OLE trial, the open-label extension study of ATTRibute-CM with the oral TTR stabilizer acoramidis in patients with ATTR-CM.

  • Educational information

    This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.

  • Faculty

    Daniel Judge, MD is a professor of medicine in cardiology at Medical University of South Carolina (MUSC) in Charleston, SC, US.

  • Disclaimer

Recommended
Details
Presenters
Comments
  • Overview

    AHA 2024 - Daniel Judge discusses the findings from the ATTRibute-CM-OLE trial, the open-label extension study of ATTRibute-CM with the oral TTR stabilizer acoramidis in patients with ATTR-CM.

  • Educational information

    This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.

  • Faculty

    Daniel Judge, MD is a professor of medicine in cardiology at Medical University of South Carolina (MUSC) in Charleston, SC, US.

  • Disclaimer

Schedule9 Dec 2024